While antagonism of TNFα with monoclonal antibodies yielded effective results in patients with rheumatoid arthritis (424) and inflammatory bowel disease (425), clinical trials for anti-TNFα in patients with chronic heart failure (RECOVER and RENAISSANCE) were terminated prematurely due to no observable benefit (426). Here, TNF is linked to inflammatory bowel disease.